Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

NCT01970540 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Adenocarcinomas
Neuroendocrine Tumors
Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy

Interventions

DRUG: lurbinectedin (PM01183)
DRUG: Doxorubicin

Sponsor

PharmaMar